A Polyphenol Signature in Urine Predicts Lower CV Risk in PREDIMED

This 2025 case-cohort study, nested within the landmark PREDIMED trial and published in BMC Medicine, identified a urinary multi-metabolite signature of eight phenolic compounds -- many derived from virgin olive oil, wine, and nuts -- that was inversely associated with cardiovascular disease incidence. According to PubMed (DOI), participants in the top quartile of the polyphenol signature had a 52% lower risk of cardiovascular events compared to the bottom quartile.

Why This Study Matters

The Mediterranean diet's cardiovascular benefit is one of the most consistent findings in nutrition epidemiology. PREDIMED itself showed a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with extra virgin olive oil or nuts. But which specific compounds within that dietary pattern actually carry the protection has remained an open question. Most prior studies relied on food frequency questionnaires, which are subject to recall bias and cannot quantify the actual bioavailable polyphenol exposure that reaches circulation.

This study took a different approach. Rather than asking participants what they ate, the researchers measured what their bodies had actually absorbed. They quantified 62 phenolic metabolites in urine using liquid chromatography-high-resolution mass spectrometry -- the gold standard for compound identification -- and used machine learning to identify which subset of metabolites best tracked Mediterranean diet adherence and predicted cardiovascular outcomes.

The result is the first prospective biomarker-based confirmation that polyphenols specifically -- not just the broader Mediterranean pattern -- are linked to lower cardiovascular risk.

How It Was Designed

The investigators conducted a case-cohort analysis nested within PREDIMED, the multi-center randomized trial that originally tested a Mediterranean diet with EVOO or mixed nuts against a low-fat control diet. From the full PREDIMED population, they selected 1,180 participants: 653 incident cardiovascular cases (stroke, myocardial infarction, CVD death, or heart failure) and a random subcohort of 603 participants for reference.

Spot urine samples were collected at baseline and again after one year of dietary intervention. Researchers measured 62 phenolic metabolites by mass spectrometry -- a methodology that allows precise quantification of bioavailable compounds rather than dietary estimates. To reduce the 62 metabolites to a tractable predictive signature, they applied elastic net regression, a regularized regression method that handles correlated predictors and selects the most informative subset.

The final signature included eight metabolites. Cox proportional-hazards models then estimated cardiovascular risk by levels of the signature, adjusting for standard confounders. The study was registered as ISRCTN 35739639.

What They Found

The eight-metabolite urinary polyphenol signature was inversely associated with cardiovascular disease in a clear dose-response pattern:

Comparison	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
Per 1 SD increase in signature	0.80 (0.68-0.94)	20% lower	Composite CVD per signature unit
Quartile 4 vs Quartile 1	0.48 (0.30-0.78)	52% lower	Highest vs lowest signature quartile
P for trend	0.002	--	Dose-response significance

Green indicates a favorable direction. The dose-response trend across signature quartiles was statistically significant.

The eight metabolites selected by the elastic net model were derived from foods central to the Mediterranean pattern: virgin olive oil (multiple olive-derived metabolites including hydroxytyrosol-related compounds), wine (resveratrol and stilbene metabolites), nuts (urolithins, derived from walnut ellagitannins), and fruits and vegetables (naringenin and related flavonoid metabolites). After one year of dietary intervention, the Mediterranean diet arms showed significantly elevated urolithin A metabolites compared to the control arm -- a direct biomarker of walnut consumption -- confirming the signature responded to diet change.

Reading the Results

The findings group around three interpretive themes worth pulling apart.

The signature is biological, not behavioral. Food frequency questionnaires capture self-reported eating patterns, which are correlated with health-conscious behaviors more broadly. The urinary signature captures what actually got absorbed -- a more direct measure of biological exposure. The fact that the signature predicts cardiovascular events independently establishes that the dietary phenolic compounds themselves carry biological signal, not just the lifestyle pattern around them.

Olive oil polyphenols are central to the signature. Multiple olive-derived metabolites appeared in the final eight-metabolite panel, alongside metabolites from wine, nuts, and produce. This is consistent with the established mechanistic literature: olive polyphenols -- particularly hydroxytyrosol and oleuropein -- have well-documented effects on oxidized LDL, endothelial function, and systemic inflammation. The signature reflects the cumulative bioavailability of these compounds across multiple food sources.

The effect size is large. A 52% lower cardiovascular risk between top and bottom quartiles, with a clear dose-response gradient, is one of the larger biomarker-cardiovascular associations in the recent literature. Even accounting for residual confounding, the magnitude suggests polyphenol exposure carries meaningful protective signal beyond what a diet score alone captures.

What Didn't Change

The study is observational by design, even though it is nested within an interventional trial. The signature was not randomized -- participants self-selected into different levels of polyphenol intake within their assigned diet arm. The 52% risk reduction is an association, not a causal claim about supplementing any single compound.

The study also does not establish which individual polyphenol within the eight-metabolite signature carries the most weight. Elastic net selects a correlated bundle of metabolites that together predict the outcome -- it does not isolate the active ingredient. Separating the relative contribution of olive-derived metabolites from nut-derived or wine-derived metabolites would require a different study design.

Broader Context

This analysis extends the PREDIMED legacy in an important direction. The original PREDIMED trial (2013, republished 2018 in NEJM) demonstrated that a Mediterranean diet supplemented with EVOO reduces major cardiovascular events by 30%. The Guasch-Ferre Harvard cohort (2022) showed 19% lower all-cause mortality and 29% lower neurodegenerative mortality with higher olive oil intake in 92,383 U.S. adults. The 2011 EFSA opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day.

This 2025 case-cohort analysis adds a missing piece: a measurable biological fingerprint of polyphenol intake that prospectively predicts cardiovascular outcomes. It strengthens the inference that polyphenols themselves -- not just the foods that carry them -- are part of the causal pathway between Mediterranean eating and lower cardiovascular risk.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• Within PREDIMED: Higher EVOO Intake Linked to 48% Lower CV Mortality
• PREDIMED Outcome-Wide: EVOO and Multiple Cardiovascular Endpoints

Source: View the original study on PubMed

Olivea's Dosage

This study did not test a specific dose of any single polyphenol. The intervention diet in PREDIMED supplied at least 4 tablespoons (about 50 mL) of extra virgin olive oil per day to the EVOO arm. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving, well above the 5 mg/day EFSA threshold; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.